A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells

Cancer Biology and Therapy

Volumn 13, Issue 8, 2012, Pages 682-694

  Balch, Curt ^a,b   Naegeli, Kaleb ^a   Nam, Seungyoon ^a,f   Ballard, Brett ^a   Hyslop, Alan ^a   Melki, Christina ^a   Reilly, Elizabeth ^c   Hur, Man Wook ^d   Nephew, Kenneth P ^a,b,e  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c XAVIER UNIVERSITY   (United States)

^d Yonsei University College of Medicine   (South Korea)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f National Cancer Center   (South Korea)

Author keywords

Epithelial to mesenchymal transition; Histone deacetylase inhibitor; microRNA; Ovarian cancer; Wnt signaling

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; MICRORNA; REACTIVE OXYGEN METABOLITE; VORINOSTAT; WNT PROTEIN; ARYLBUTYRIC ACID DERIVATIVE; MESSENGER RNA; OSU-HDAC42 COMPOUND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENETIC CODE; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; OVARY CANCER; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; CLUSTER ANALYSIS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; OVARY TUMOR; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CLUSTER ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICRORNAS; MOLECULAR SEQUENCE ANNOTATION; OVARIAN NEOPLASMS; PHENYLBUTYRATES; RNA, MESSENGER; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 84929510834     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt20086     Document Type: Article

References (72)

1. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009; 10:32-42; PMID:19065135; http://dx.doi.org/10.1038/ nrg2485.
2. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26:5541-52; PMID:17694093; http://dx.doi.org/10.1038/sj.onc.1210620.
3. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25:84-90; PMID:17211407; http://dx.doi.org/10.1038/nbt1272.
4. Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 2009; 15:3947-57; PMID:19509170; http://dx.doi.org/10.1158/1078-0432.CCR-08- 2787.
5. Lu Q, Wang DS, Chen CS, Hu YD, Chen CS. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem 2005; 48:5530-5; PMID:16107152; http://dx.doi.org/10.1021/jm0503749.
6. Yang YT, Balch C, Kulp SK, Mand MR, Nephew KP, Chen CS. A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. Neoplasia 2009; 11:552-63; PMID:19484144.
7. Sargeant AM, Rengel RC, Kulp SK, Klein RD, Clinton SK, Wang YC, et al. OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2008; 68:3999-4009; PMID:18483287; http://dx.doi.org/10.1158/0008-5472.CAN-08-0203.
8. Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, et al. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology 2007; 46:1119-30; PMID:17654699; http://dx.doi.org/10. 1002/hep.21804.
9. Bai LY, Omar HA, Chiu CF, Chi ZP, Hu JL, Weng JR. Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells. Cancer Chemother Pharmacol 2011; 68:489-96; PMID:21072520; http://dx.doi.org/10.1007/s00280-010-1501-z.
10. Zimmerman B, Sargeant A, Landes K, Fernandez SA, Chen CS, Lairmore MD. Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma. Leuk Res 2011; 35:1491-7; PMID:21802726; http://dx.doi.org/10.1016/j.leukres.2011.07.015.
11. Liu YL, Yang PM, Shun CT, Wu MS, Weng JR, Chen CC. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy 2010; 6:1057-65; PMID:20962572; http://dx.doi.org/10.4161/ auto.6.8.13365.
12. Jacob A, Oblinger J, Bush ML, Brendel V, Santarelli G, Chaudhury AR, et al. Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. Laryngoscope 2012; 122:174-89; PMID:22109824; http://dx.doi.org/10.1002/lary.22392.
13. Takai N, Narahara H. Histone deacetylase inhibitor therapy in epithelial ovarian cancer. J Oncol 2010; 2010:458431.
14. Balch C, Nephew KP. The role of chromatin, microRNAs and tumor stem cells in ovarian cancer. Cancer Biomark 2010; 8:203-21; PMID:22045354.
15. Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009; 15:3970-7; PMID:19509171; http://dx.doi.org/10.1158/1078-0432. CCR-08-2786.
16. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-92; PMID:17320506; http://dx.doi.org/10.1016/j.cell.2007.01.029.
17. Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 2010; 16:1119-28; PMID:20145172; http://dx.doi.org/10.1158/1078-0432. CCR-09-2642.
18. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67:8699-707; PMID:17875710; http://dx.doi.org/10.1158/0008-5472.CAN-07-1936.
19. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 2008; 105:7004-9; PMID:18458333; http://dx.doi.org/10.1073/pnas.0801615105.
20. Cowden Dahl KD, Dahl R, Kruichak JN, Hudson LG. The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia 2009; 11:1208-15; PMID:19881956.
21. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008; 14:2690-5; PMID:18451233; http://dx.doi.org/10.1158/1078-0432.CCR-07-1731.
22. Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG, et al. Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic leukemia. Blood 2012; 119:1162-72; PMID:22096249; http://dx.doi.org/10.1182/blood-2011-05-351510.
23. Rhodes LV, Nitschke AM, Segar HC, Martin EC, Driver JL, Elliott S, et al. The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncol Rep 2012; 27:10-6; PMID:21971930.
24. Shin S, Lee EM, Cha HJ, Bae S, Jung JH, Lee SM, et al. MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells. Int J Oncol 2009; 35:1343-52; PMID:19885557.
25. Lee EM, Shin S, Cha HJ, Yoon Y, Bae S, Jung JH, et al. Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int J Mol Med 2009; 24:45-50; PMID:19513533.
26. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006; 66:1277-81; PMID:16452179; http://dx.doi.org/10.1158/0008-5472.CAN-05-3632.
27. Diederichs S, Haber DA. Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. Cancer Res 2006; 66:6097-104; PMID:16778182; http://dx.doi.org/10.1158/0008-5472.CAN- 06-0537.
28. Pe'er D, Hacohen N. Principles and strategies for developing network models in cancer. Cell 2011; 144:864-73; PMID:21414479; http://dx.doi.org/10. 1016/j. cell.2011.03.001.
29. Ulitsky I, Maron-Katz A, Shavit S, Sagir D, Linhart C, Elkon R, et al. Expander: from expression microarrays to networks and functions. Nat Protoc 2010; 5:303-22; PMID:20134430; http://dx.doi.org/10.1038/nprot.2009.230.
30. Ovcharenko I, Nobrega MA, Loots GG, Stubbs L. ECR Browser: a tool for visualizing and accessing data from comparisons of multiple vertebrate genomes. Nucleic Acids Res 2004; 32:280-6; PMID:15215395; http://dx.doi.org/10.1093/nar/ gkh355.
31. Wang X, Xuan Z, Zhao X, Li Y, Zhang MQ. High-resolution human core-promoter prediction with CoreBoost-HM. Genome Res 2009; 19:266-75; PMID:18997002; http://dx.doi.org/10.1101/gr.081638.108.
32. Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 2005; 21:3448-9; PMID:15972284; http://dx.doi.org/10.1093/ bioinformatics/bti551.
33. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003; 2:151-63; PMID:12589032.
34. Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, et al. LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res 2010; 70:2296-306; PMID:20215510; http://dx.doi.org/ 10.1158/0008-5472.CAN-09-3141.
35. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102:15545-50; PMID:16199517; http://dx.doi.org/10.1073/pnas.0506580102.
36. Anderson K, Lawson KA, Simmons-Menchaca M, Sun L, Sanders BG, Kline K. Alpha-TEA plus cisplatin reduces human cisplatin-resistant ovarian cancer cell tumor burden and metastasis. Exp Biol Med (Maywood) 2004; 229:1169-76; PMID:15564444.
37. Arafa SA, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA, et al. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide-3-kinase/Akt signaling pathway. Cancer Res 2009; 69:8910-7; PMID:19903849; http://dx.doi.org/10.1158/0008-5472.CAN-09-1543.
38. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004; 22:4700-10; PMID:15505275; http://dx.doi.org/10.1200/JCO.2004.04.070.
39. Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 2005; 24:1053-65; PMID:15558012; http://dx.doi.org/10.1038/sj.onc.1208298.
40. Warner DR, Greene RM, Pisano MM. Cross-talk between the TGFbeta and Wnt signaling pathways in murine embryonic maxillary mesenchymal cells. FEBS Lett 2005; 579:3539-46; PMID:15955531; http://dx.doi.org/10.1016/j.febslet.2005.05. 024.
41. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch and Hedgehog pathways. Nat Rev Clin Oncol 2011; 8:97-106; PMID:21151206; http://dx.doi.org/10.1038/nrclinonc.2010.196.
42. Ying Y, Tao Q. Epigenetic disruption of the WNT/ beta-catenin signaling pathway in human cancers. Epigenetics 2009; 4:307-12; PMID:19633433; http://dx.doi.org/10.4161/epi.4.5.9371.
43. Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010; 11:621-32; PMID:20683470; http://dx.doi.org/10.1038/nrm2952.
44. Tait SW, Green DR. Caspase-independent cell death: leaving the set without the final cut. Oncogene 2008; 27:6452-61; PMID:18955972; http://dx.doi.org/10.1038/onc.2008.311.
45. Vandenabeele P, Vanden Berghe T, Festjens N. Caspase inhibitors promote alternative cell death pathways. Sci STKE 2006; 2006:44.
46. Smiley ST, Reers M, Mottola-Hartshorn C, Lin M, Chen A, Smith TW, et al. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA 1991; 88:3671-5; PMID:2023917; http://dx.doi.org/10.1073/pnas.88.9.3671.
47. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21:103-7; PMID:9916800; http://dx.doi.org/10.1038/5047.
48. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31:141-9; PMID:11992124; http://dx.doi.org/10.1038/ng892.
49. 2/M arrest and autophagy. Cancer 2011; 117:4424-38; PMID:21491416; http://dx.doi.org/10.1002/cncr.26073.
50. Arzenani MK, Zade AE, Ming Y, Vijverberg SJ, Zhang Z, Khan Z, et al. Genomic DNA hypomethylation by histone deacetylase inhibition implicates DNMT1 nuclear dynamics. Mol Cell Biol 2011; 31:4119- 28; PMID:21791605; http://dx.doi.org/10.1128/ MCB.01304-10.
51. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008; 27:7274-84; PMID:18806826; http://dx.doi.org/10.1038/onc.2008.333.
52. Huang PH, Chen CH, Chou CC, Sargeant AM, Kulp SK, Teng CM, et al. Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. Mol Pharmacol 2011; 79:197-206; PMID:20959362; http://dx.doi.org/10.1124/mol.110.067702.
53. Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 2006; 5:2086-95; PMID:16928830; http://dx.doi.org/10.1158/1535-7163.MCT-06-0111.
54. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141:69-80; PMID:20371346; http://dx.doi.org/10.1016/j.cell.2010.02. 027.
55. Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D. Tissue transglutaminase links TGFβ, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. [Epub ahead of print]. Oncogene 2011; PMID:21963846; http://dx.doi.org/10.1038/onc.2011.429.
56. Stronach EA, Chen M, Maginn EN, Agarwal R, Mills GB, Wasan H, et al. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia 2011; 13:1069-80; PMID:22131882.
57. Hrzenjak A, Kremser ML, Strohmeier B, Moinfar F, Zatloukal K, Denk H. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J Pathol 2008; 216:495-504; PMID:18850582; http://dx.doi.org/10.1002/path.2434.
58. Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih IeM, Zhang Y, et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 2008; 3:2436; PMID:18560586; http://dx.doi.org/10.1371/journal. pone.0002436.
59. Galimberti S, Canestraro M, Maffei R, Marasca R, Guerrini F, Piaggi S, et al. Vorinostat interferes with Wnt and NFkappaB pathways in the M-07e cell line. Leukemia 2009; 23:1935-8; PMID:19626048; http://dx.doi.org/10.1038/leu. 2009.119.
60. Sikandar S, Dizon D, Shen X, Li Z, Besterman J, Lipkin SM. The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. Oncotarget 2010; 1:596-605; PMID:21317455.
61. Wiltse J. Mode of action: inhibition of histone deacetylase, altering WNT-dependent gene expression and regulation of beta-catenin-developmental effects of valproic acid. Crit Rev Toxicol 2005; 35:727-38; PMID:16417040; http://dx.doi.org/10.1080/10408440591007403.
62. Tysnes BB. Tumor-initiating and -propagating cells: cells that we would like to identify and control. Neoplasia 2010; 12:506-15; PMID:20651980.
63. Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K, et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev 2010; 24:1389-402; PMID:20595231; http://dx.doi.org/10.1101/gad. 1940710.
64. Krizhanovsky V, Lowe SW. Stem cells: The promises and perils of p53. Nature 2009; 460:1085-6; PMID:19713919; http://dx.doi.org/10.1038/4601085a.
65. Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 2008; 153:657-68; PMID:18059320; http://dx.doi.org/10.1038/sj. bjp.0707608.
66. Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY, et al. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res 2005; 65:7386-92; PMID:16103091; http://dx.doi.org/10.1158/0008-5472.CAN-04-3433.
67. Li D, Marchenko ND, Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 2011; 18:1904-13; PMID:21637290; http://dx.doi.org/10.1038/cdd.2011.71.
68. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26:745-52; PMID:17540599; http://dx.doi.org/10.1016/j.molcel.2007.05.010.
69. Turley EA, Veiseh M, Radisky DC, Bissell MJ. Mechanisms of disease: epithelial-mesenchymal transition-does cellular plasticity fuel neoplastic progression? Nat Clin Pract Oncol 2008; 5:280-90; PMID:18349857; http://dx.doi.org/10.1038/ncponc1089.
70. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006; 66:11954-66; PMID:17178894; http://dx.doi.org/10. 1158/0008-5472.CAN-06-1666.
71. Thomson JM, Parker J, Perou CM, Hammond SM. A custom microarray platform for analysis of microRNA gene expression. Nat Methods 2004; 1:47-53; PMID:15782152; http://dx.doi.org/10.1038/nmeth704.
72. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19:185-93; PMID:12538238; http://dx.doi.org/10.1093/bioinformatics/19.2.185.